PUBLISHER: The Business Research Company | PRODUCT CODE: 1429684
PUBLISHER: The Business Research Company | PRODUCT CODE: 1429684
A veterinary vaccine is a biological preparation designed to stimulate the immune response of an animal, aiming to reduce animal suffering, prevent the transmission of microorganisms within the animal population, and enhance the immune strength of animals for improved health. Additionally, veterinary vaccines play a crucial role in preventing the transmission of diseases from animals to humans.
Various types of veterinary vaccines include live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, and other vaccine variants. Inactivated vaccines, distinct from live attenuated vaccines, consist of dead or inactivated viruses and bacteria. The diseases targeted by these vaccines encompass anaplasmosis, canine parvovirus, foot and mouth disease, Newcastle disease, distemper disease, influenza, and porcine reproductive and respiratory syndrome. The application areas for veterinary vaccines extend to both livestock vaccines and companion animal vaccines.
The veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides veterinary vaccines statistics, including veterinary vaccines industry global market size, regional shares, competitors with veterinary vaccines share, detailed veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the veterinary vaccines industry. The veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The veterinary vaccines market size has grown strongly in recent years. It will grow from $12.47 billion in 2023 to $13.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The expansion observed in the historical period can be attributed to factors such as the growth of emerging markets, heightened pet spending, increased disease prevalence, a rise in poultry disease outbreaks, and an increased incidence of zoonotic diseases.
The veterinary vaccines market size is expected to see strong growth in the next few years. It will grow to $17.85 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to factors such as economic growth, the increasing penetration of pet insurance, a rise in pet ownership, an increase in government initiatives, and growing awareness about animal health. Major trends in the forecast period include investments in the development of nanoparticles, increased production of subunit and virus-such as particle-based vaccines, manufacturing vaccines for diseases such as parvovirus, distemper, and adenovirus to support the mandatory and regular vaccination schedules for pet owners, heightened investment in technological advancements, increased focus on toxoid vaccines, a greater emphasis on investment in mRNA vaccines, and a surge in strategic collaborations and partnerships.
The veterinary vaccines market is experiencing growth driven by the increasing number of animals afflicted with various diseases, creating a demand for vaccines to prevent and treat these conditions. A report from the Animal and Plant Health Agency highlights 3289 new TB herd incidents detected in England, underscoring the significance of diseases such as bovine tuberculosis in animals. The prevalence of diseases, including chronic ailments such as bovine tuberculosis in cattle, contributes to the heightened need for veterinary vaccines, offering preventive and therapeutic solutions.
The growth of the veterinary vaccine market is further propelled by the rising demand for animal-derived food products. This category encompasses a variety of items, such as beef, pork, chicken, fish, milk, cheese, butter, eggs, and other ingredients sourced from animals. The prevention of diseases in animals, driven by regulatory compliance and the imperative for food safety, leads to an increased adoption of veterinary vaccines. These vaccines not only protect animal health but also ensure the prevention of disease outbreaks, assuring consumers of the quality and safety of food products. The global meat supply is projected to reach 374 Mt by 2030, with a predicted 14% increase in meat protein consumption globally compared to 2020, emphasizing the crucial role of veterinary vaccines in supporting the demand for animal-derived food products.
In the veterinary vaccines market, companies are actively forming strategic partnerships and collaborations to expand into new geographical regions and engage in joint research and development projects. Merck Animal Health, for example, established a four-year strategic alliance with Iowa State University, focusing on innovative solutions in animal health through collaborative efforts in research and development, manufacturing, technology exploration, and business expansion. Such partnerships aim to address animal health challenges globally. MSD Animal Health also entered a strategic partnership with Vinovo, enhancing the vaccination process and improving bird welfare by combining MSD Animal Health's vaccine product line with Vinovo's vaccine delivery system. Additionally, Wageningen bio veterinary research collaborated with Ceva to enhance research on emerging and reemerging diseases for animals.
Key players in the veterinary vaccine market are investing in innovation to maintain a competitive edge. Merck Animal Health, for instance, introduced a new three-in-one swine vaccine named Circumvent CML in June 2023. This vaccine offers protection against Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. Circumvent CML combines multiple antigens and adjuvant systems in a single bottle, simplifying the vaccination process and reducing stress for animals and caretakers.
The regulatory landscape of the veterinary vaccines market is governed by authorities such as the European Medicines Agency and the US Center for Veterinary Biologics. In Europe, veterinary vaccine companies must adhere to specific technical requirements outlined in Directive 2001/82/EC and European Pharmacopoeia (Ph. Eur.). Safety tests are mandatory for approval, involving in vitro titration for activated vaccines and serological tests for inactivated vaccines. Batch standards for inactivated vaccines necessitate a dose double the standard for each batch, while activated vaccines must undergo testing with a batch ten times the standard dose. These regulatory measures ensure the safety and efficacy of veterinary vaccines.
Major companies operating in the veterinary vaccines market report are Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Elanco Animal Health Incorporated, Ceva Sante Animale., Virbac Group, HIPRA, Biogenesis Bago, Kyoritsu Seiyaku Corporation, Phibro Animal Health Corporation, Century Vaccines Limited, BASF India Ltd., Bayer Animal Health Cadila Vaccines Ltd., Cargill India Pvt. Ltd., China Animal Healthcare Ltd., Merck/MSD Animal Health, Jurox Pty Ltd., Nimrod Veterinary Products Ltd., Bimeda, Animalcare, MSD Animal Health, Interfeed, Biotex Plus Ltd., Belfarmacom, Zoetis, IDT Biologika, UCBVET, Lemavet, Syntec, Sauvet, Vetanco, Chemo Argentina, Brouwer, Agrovet Market Animal Health, Sanofi Animal Health Inc., Novartis Animal Health, DBK Pharma S.A.E.
North America was the largest region in the veterinary vaccines market in 2023. Asia-Pacific was the second-largest region in the global veterinary vaccines market analysis. The regions covered in the veterinary vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the veterinary vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain
The veterinary vaccines market consists of sales of messenger RNA vaccine, viral vector vaccine, and subunit vaccine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Veterinary Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on veterinary vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for veterinary vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The veterinary vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of covid 19 on supply chains and consumption patterns.